ESTROGEL (estradiol) by Ascend Therapeutics is estrogen receptor agonists [moa]. First approved in 2004.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
ESTROGEL is a transdermal metered-dose gel formulation of estradiol, a synthetic estrogen receptor agonist approved in 2004 for hormone replacement therapy. It works by binding to estrogen receptors to alleviate menopausal symptoms in women. The transdermal delivery route provides an alternative to oral estrogen therapy with potentially improved tolerability.
Product is in late-stage lifecycle with modest Part D utilization (4,587 claims in 2023), suggesting limited team expansion opportunities as patent expiration approaches.
Estrogen Receptor Agonists
Estrogen
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on ESTROGEL at Ascend Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moESTROGEL offers limited career growth opportunities given its approaching loss of exclusivity and modest commercial footprint ($1M Part D spending). Professionals joining this team should expect roles focused on defending market share, optimizing pricing/access, and preparing transition strategies rather than launching or scaling a growth-stage product.